CA3218191A1 - Compositions for treatment of neurodegenerative conditions - Google Patents

Compositions for treatment of neurodegenerative conditions Download PDF

Info

Publication number
CA3218191A1
CA3218191A1 CA3218191A CA3218191A CA3218191A1 CA 3218191 A1 CA3218191 A1 CA 3218191A1 CA 3218191 A CA3218191 A CA 3218191A CA 3218191 A CA3218191 A CA 3218191A CA 3218191 A1 CA3218191 A1 CA 3218191A1
Authority
CA
Canada
Prior art keywords
ene
triol
pharmaceutical composition
ethynylandrost
motor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3218191A
Other languages
English (en)
French (fr)
Inventor
Clarence Nathaniel Ahlem
Christopher L. Reading
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biovie Inc
Original Assignee
Biovie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovie Inc filed Critical Biovie Inc
Publication of CA3218191A1 publication Critical patent/CA3218191A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
CA3218191A 2021-05-18 2022-05-02 Compositions for treatment of neurodegenerative conditions Pending CA3218191A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163189880P 2021-05-18 2021-05-18
US63/189,880 2021-05-18
PCT/US2022/027294 WO2022245532A1 (en) 2021-05-18 2022-05-02 Compositions for treatment of neurodegenerative conditions

Publications (1)

Publication Number Publication Date
CA3218191A1 true CA3218191A1 (en) 2022-11-24

Family

ID=84141848

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3218191A Pending CA3218191A1 (en) 2021-05-18 2022-05-02 Compositions for treatment of neurodegenerative conditions

Country Status (7)

Country Link
US (1) US20240108636A1 (https=)
EP (1) EP4341271A4 (https=)
JP (1) JP2024519079A (https=)
AU (1) AU2022275684A1 (https=)
CA (1) CA3218191A1 (https=)
MX (1) MX2023013616A (https=)
WO (1) WO2022245532A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024054452A1 (en) * 2022-09-06 2024-03-14 Biovie Inc. Methods for the treatment of mild cognitive impairment
WO2025155561A1 (en) * 2024-01-16 2025-07-24 Biovie Inc. Methods of treating long covid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070015763A1 (en) * 2005-07-12 2007-01-18 Pfizer Inc Treatment of psychosis associated with parkinson's disease and subcortical dementias using a combination of an atypical antipsychotic with a dopamine agonist
DK2273994T3 (en) * 2008-04-03 2016-02-01 Neurmedix Inc PHARMACEUTICAL FORMS OF A MEDICINE

Also Published As

Publication number Publication date
MX2023013616A (es) 2024-01-17
WO2022245532A1 (en) 2022-11-24
US20240108636A1 (en) 2024-04-04
EP4341271A1 (en) 2024-03-27
AU2022275684A1 (en) 2023-11-16
JP2024519079A (ja) 2024-05-08
EP4341271A4 (en) 2025-04-30

Similar Documents

Publication Publication Date Title
AU2021201390B2 (en) Pharmaceutical compositions comprising glitazones and nrf2 activators
US20240108636A1 (en) Compositions for treatment of neurodegenerative conditions
NZ588505A (en) Dosing regimen for a selective S1P1 receptor agonist (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one
JP7557185B2 (ja) 免疫応答を調節するｇａｂａの能力の強化
Quinn Anti-parkinsonian drugs today
JP2025510916A5 (https=)
US20230066347A1 (en) Ketamine treatment for amyotrophic lateral sclerosis
AU4748100A (en) Glycine cleavage system inhibitors as potential antipsychotics
US11304923B2 (en) Use of a benzoate containing composition to treat glycine encephalopathy
CN104013638A (zh) 当药黄素及其衍生物的用途
US9504679B2 (en) Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20110117070A1 (en) Compositions and methods for treating headache
JP2024527175A5 (https=)
CN111265523A (zh) 小檗碱、人参皂苷组合物在制备预防和/或治疗糖尿病伴发抑郁症的药物中的应用
KR102631399B1 (ko) 폴마콕시브 및 프레가발린을 포함하는 통증 치료용 약제학적 조성물
Mousavi et al. Evaluation of the neuroprotective effect of dextromethorphan in the acute phase of ischaemic stroke
CN102648915B (zh) 一种治疗或预防神经病理性疼痛的药物组合物
RU2572720C1 (ru) Комплексное антиникотиновое средство
JP2009196972A (ja) 医薬組成物
EP4331587A1 (en) Composition for preventing or treating metabolic diseases, containing tricyclo derivative compound
TW201334776A (zh) 醫藥組成物
US20250302845A1 (en) Selective dopamine increase
JP2020100601A (ja) 一酸化窒素合成酵素活性化剤
CN109381458B (zh) 甲吡唑及其盐在制备抗癫痫药物中的用途
CN109806398B (zh) Fxr激动剂与瘦素联用在制备抗肥胖药物中的应用

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240913

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240913

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240913

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20250324

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250425

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250425